NCT04240678 is a NA clinical trial of Electronic HBV Alert in Hepatitis B, sponsored by University of California, Davis.

Who is sponsoring NCT04240678?

NCT04240678 is sponsored by University of California, Davis.

What drugs are being tested in NCT04240678?

Interventions in NCT04240678: Electronic HBV Alert.

What condition does NCT04240678 study?

NCT04240678 studies Hepatitis B.

Is NCT04240678 still recruiting?

NCT04240678 is currently completed. Last updated 11 August 2021.

Are results published for NCT04240678?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-08-11 · How we verify

NCT04240678

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of an Electronic Medical Record (EMR) Alert on Hepatitis B Screening

Completed NA Results posted Last updated 11 August 2021

What this trial tests

NA trial testing Electronic HBV Alert in Hepatitis B in 8,299 participants. Completed in 1 July 2021.

Timeline

1 January 2016

Primary endpoint
1 July 2019

1 July 2021

Quick facts

Lead sponsor	University of California, Davis
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	screening
Enrollment	8,299
Start date	1 January 2016
Primary completion	1 July 2019
Estimated completion	1 July 2021

Drugs / interventions tested

Electronic HBV Alert

Conditions studied

Hepatitis B — all drugs for Hepatitis B →

Sponsor

University of California, Davis

Who can join

Adults 18 to 75, any sex, with Hepatitis B. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Serum Hepatitis B Surface Antigen Completion Primary · up to 12 months

Number of patients who have completed the HBsAg test

Group	Value	95% CI
HBV Alert Group	389
Control Group	177

Serum Hepatitis B Surface Antigen Positivity Secondary · up to 12 months

Number of patients with testing positive for HBsAg

Group	Value	95% CI
HBV Alert Group	15
Control Group	13

Sponsor's own description

Asian and Pacific Islander Americans at risk, but never tested for chronic hepatitis B have been randomized to receive an electronic alert in their electronic medical chart to remind primary care physicians to screen them for chronic hepatitis B.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Electronic health record alerts enhance mass screening for chronic hepatitis B.
Chak E, Li CS, Chen MS, MacDonald S, et al · · 2020 · cited 13× · PMID 33154429 · DOI 10.1038/s41598-020-75842-8

Verify or expand the search:

Other recruiting trials for Hepatitis B

Currently open trials in the same condition.

NCT04843852 — TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B · Phase 1 · recruiting
NCT07168356 — A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease · Phase 1 · recruiting
NCT06947356 — Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads · NA · recruiting
NCT06537414 — A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living Wit · Phase 2 · active not recruiting
NCT06623071 — Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation FA 96/384 · recruiting

Other University of California, Davis trials

Trials by the same sponsor.

NCT07024498 — Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment · NA · not yet recruiting
NCT07322133 — Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) · Phase 4 · recruiting
NCT07384767 — Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing · Phase 2 · not yet recruiting
NCT07267494 — Image-Guided Herniorrhaphy Study · NA · not yet recruiting
NCT04614714 — Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants · Phase 2, PHASE3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04240678 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Davis
Last refreshed: 11 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04240678.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing